Software will aid optimizing pre-clinical data management in accordance with global standards and guidelines. Seoul, SOUTH KOREA August 4rd – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in Biosimulation, today announced that a Korea Institute of Toxicology (KIT) have decided to implement Certara’s Pinnacle 21 Enterprise data conformance and submission software and SEND Explorer pre-clinical … Continued
DNDi Utilizing Pinnacle 21 Enterprise (P21E), Certara’s Data Science platform for Biostatistics, Data Management, and Data Standards to Streamline Clinical Data Flow PRINCETON, NJ/NAIROBI, KE, 2023 年 7 月 31 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation software and advanced drug development solutions, today announced a partnership with the Drugs for Neglected Diseases initiative … Continued
PRINCETON, N.J.— 2023 年 6 月 20 日 — Certara, Inc. （纳斯达克股票代码：CERT), today announced it has acquired Drug Interaction Solutions from the University of Washington. This transaction brings a world-renowned team of scientists and the Drug Interaction Database (“DIDB”), the leading subscription-based informatics solution for the identification of pharmacokinetic (PK) drug interactions, to Certara. Used by over … Continued
Princeton, N.J., 2023 年 6 月 13 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced the appointment of Shelia Rocchio to the position of Chief Marketing Officer. In this role, Ms. Rocchio will be responsible for leading the Certara marketing function, building data driven marketing practices, driving lead generation, and further developing Certara’s brand … Continued
Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform PRINCETON, N.J.— 2023 年 6 月 12 日. Certara®, the global leader in biosimulation, today announced the launch of version 8.4 of its Phoenix™ platform, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. Version 8.4 delivers new features driven by … Continued
Trial design and execution now accelerated by deep learning and data fabric capabilities. PRINCETON, NJ June 8 — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, is integrating new AI capabilities and data connectivity into its clinical trials outcome analytics platform, CODEX. The additions enable clinical trial teams to draw reliable conclusions around therapeutic … Continued
Next generation automation for Medical Writers to streamline the creation of regulatory documents Certara is excited to announce that SynchrogenixTM Writer is the latest Certara software to incorporate powerful deep learning capabilities. AI is now woven seamlessly into Sychrogenix Writer’s medical writing process, ushering in the next generation of regulatory document creation. This upgrade supports … Continued
Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator is being used to verify and expand biosimulation models for assessing virtual bioequivalence (VBE) of complex generic drugs PRINCETON, N.J.— 2023 年 2 月 7 日. Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded work with the University of Florida and the University of Rhode … Continued
Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system disorders including addiction and chronic pain Princeton, N.J., 2023 年 1 月 10 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announces that the U.S. National Institutes of Health (NIH) has awarded a contract to Certara for ongoing toxicology … Continued
PRINCETON, N.J., 2023 年 1 月 9 日 — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that Ghent University (Belgium) submitted the successful bid for the 2021/22 Grant and Partnership Scheme (GPS). Funding will now be provided for a two-year Postdoctoral Fellowship research project titled ‘Optimisation of therapy in patients with chronic kidney disease: … Continued
